348 related articles for article (PubMed ID: 32608373)
1. Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges.
Luzzi S; Giotta Lucifero A; Brambilla I; Magistrali M; Mosconi M; Savasta S; Foiadelli T
Acta Biomed; 2020 Jun; 91(7-S):18-31. PubMed ID: 32608373
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
Ren PP; Li M; Li TF; Han SY
Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
5. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
[TBL] [Abstract][Full Text] [Related]
6. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
7. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
9. Innovative therapies for malignant brain tumors: the road to a tailored cure.
Giotta Lucifero A; Luzzi S; Brambilla I; Trabatti C; Mosconi M; Savasta S; Foiadelli T
Acta Biomed; 2020 Jun; 91(7-S):5-17. PubMed ID: 32608372
[TBL] [Abstract][Full Text] [Related]
10. Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas.
Giotta Lucifero A; Luzzi S; Brambilla I; Schena L; Mosconi M; Foiadelli T; Savasta S
Acta Biomed; 2020 Jun; 91(7-S):61-78. PubMed ID: 32608376
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
12. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
Riccione K; Suryadevara CM; Snyder D; Cui X; Sampson JH; Sanchez-Perez L
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741761
[TBL] [Abstract][Full Text] [Related]
13. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.
Chuntova P; Chow F; Watchmaker PB; Galvez M; Heimberger AB; Newell EW; Diaz A; DePinho RA; Li MO; Wherry EJ; Mitchell D; Terabe M; Wainwright DA; Berzofsky JA; Herold-Mende C; Heath JR; Lim M; Margolin KA; Chiocca EA; Kasahara N; Ellingson BM; Brown CE; Chen Y; Fecci PE; Reardon DA; Dunn GP; Liau LM; Costello JF; Wick W; Cloughesy T; Timmer WC; Wen PY; Prins RM; Platten M; Okada H
Neuro Oncol; 2021 Mar; 23(3):356-375. PubMed ID: 33367885
[TBL] [Abstract][Full Text] [Related]
14. Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).
Giotta Lucifero A; Luzzi S
Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33803885
[TBL] [Abstract][Full Text] [Related]
15. CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.
Rotolo R; Leuci V; Donini C; Cykowska A; Gammaitoni L; Medico G; Valabrega G; Aglietta M; Sangiolo D
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212634
[TBL] [Abstract][Full Text] [Related]
16. The current state of immunotherapy for gliomas: an eye toward the future.
Fecci PE; Sampson JH
J Neurosurg; 2019 Sep; 131(3):657-666. PubMed ID: 31473668
[TBL] [Abstract][Full Text] [Related]
17. Cellular immunotherapy for malignant gliomas.
Lin Y; Okada H
Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
[TBL] [Abstract][Full Text] [Related]
18. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Salinas RD; Durgin JS; O'Rourke DM
CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
Bagley SJ; Desai AS; Linette GP; June CH; O'Rourke DM
Neuro Oncol; 2018 Oct; 20(11):1429-1438. PubMed ID: 29509936
[TBL] [Abstract][Full Text] [Related]
20. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.
Weiss T; Weller M; Guckenberger M; Sentman CL; Roth P
Cancer Res; 2018 Feb; 78(4):1031-1043. PubMed ID: 29222400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
